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In gastric cancer (GC) the loss of genomic stability represents a key molecular step that occurs early in the
carcinogenesis process and creates a permissive environment for the accumulation of genetic and epigenetic
alterations in tumor suppressor genes and oncogenes. It is widely accepted that GC can follow at least two
major genomic instability pathways, microsatellite instability (MSI) and chromosome instability (CIN). MSI is
responsible for a well-defined subset of GCs. CIN represents a more common pathway comprising
heterogeneous subsets of GC. In addition to MSI and CIN, the CpG islands methylator phenotype (CIMP) plays
an important role in gastric carcinogenesis. CIMP may lead to the transcriptional silencing of various genes in
gastric carcinogenesis. Intriguingly, more recently in addition to CpG island hypermethylation, a global DNA
demethylation, that precedes genomic damage, has been observed in GC. Thus, epigenetic alterations may
play a relevant role in gastric carcinogenesis as alternative mechanisms. Evidence suggests that although MSI,
CIN and CIMP phenotypes can be distinguished from one another, there might be some degree of overlap. This
review describes our current knowledge of the instability pathways in gastric carcinogenesis and the potential
clinical applications for different forms of genomic instability in GC.
Key words: gastric cancer, genomic instability, microsatellite instability (MSI), chromosomal instability (CIN), CpG
island methylator phenotype (CIMP), clinical implications
introduction
Although the incidence and mortality of gastric cancer (GC) have
fallen over the past 70 years, GC continues to be the second
leading cause of cancer death and the fourth most common
malignant neoplasia across the world [1–3]. GC still represents
a major clinical challenge because it has a poor prognosis, with
a modest 5-year survival of about 5% [4], and limited treatment
options, due to its relative resistance to radiotherapy and
chemotherapy. At present, tumor stage provides the major
prognostic variables used in clinical management of GC patients.
However, GC with similar morphology may display different
biological aggressiveness, prognosis and response to therapy.
It is now widely accepted that GC, in common with most
human tumors, develops through the accumulation of genetic
and epigenetic alterations affecting oncogenes and tumor
suppressor genes and that alterations in mechanisms that control
genomic instability lay at the base of this process [5, 6]. Current
knowledge on the molecular mechanisms underlying gastric
carcinogenesis indicate that two major genomic instability
pathways are involved in the pathogenesis of GC, microsatellite
instability (MSI) and chromosome instability (CIN). MSI,
defined as the presence of replication errors in simple repetitive
microsatellite sequences, is responsible for a well-defined subset
of GC and has been recognized as one of the earliest changes in
GC carcinogenesis [6–8]. CIN, characterized by gross
chromosomal alterations, either qualitative or quantitative, is
a more common pathway that may comprise
clinicopathologically and molecularly heterogeneous tumors [9].
From a molecular viewpoint, there is evidence that gastric
carcinogenesis is a long-term multistep process associated with
alteration in genomic stability and accumulation of multiple
gene abnormalities. According to a metaplasia–adenoma–
carcinoma progression model [10], a sequence of molecular
changes related to MSI and CIN phenotypes may be observed in
gastric carcinogenesis (Figure 1). Although the MSI and CIN
phenotypes can be distinguished from one another, recent
evidence suggests that there might be some degree of overlap
[11] (Figure 2).
In addition to genetic alterations, epigenetic alterations are
also involved in carcinogenesis. In particular in gastric
carcinogenesis, the CpG islands methylator phenotype (CIMP),
characterized by an abnormal degree of hypermethylation in the
context of CpG islands localized in gene promoters, may lead to
the transcriptional silencing of various genes including E-
cadherin, p16, p15 and hMLH1 [5]. Interestingly, GC
hypermethylation of gene promoters progressively increases
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with histopathology progression from chronic gastritis,
intestinal metaplasia and adenoma to carcinoma [12]. Thus,
CIMP may represent a distinct pathway in GC, although there is
evidence of a high frequency of CIMP phenotype in GC
displaying MSI phenotype. Intriguingly, increased DNA
hypomethylation and hypermethylation have been shown to
correlate with increased genomic damage and a global DNA
demethylation has been shown to precede genomic damage in
a significant subset of colon and gastric cancers [13] (Figure 3).
Although the detailed mechanisms that induce genomic
instability in GC remain to be fully elucidated, the enhancement
in understanding of the molecular basis underlying the
malignant transformation of gastric mucosa may lead to the
identification of new diagnostic and prognostic molecular
markers as well as novel treatments modalities.
In this review recent advances in our knowledge on patterns
of genomic instability in GC are summarized and their clinical
relevance is also discussed.
microsatellite instability phenotype in
gastric cancer
Microsatellite instability (MSI) is defined as the presence of
replication errors resulting in insertions/deletions of bases
within nucleotide repeats, known as microsatellite regions. MSI
has initially been reported in colorectal cancer and it represents
a hallmark of the hereditary non-polyposis colorectal cancer
(HNPCC) syndrome. Thus, MSI may occur in GCs developing
in the context of HNPCC and it has been also reported in
a subset of sporadic GCs ranging from 25% to 50% [6, 14].
MSI can be easily identified by analysing paired tumor and
normal DNA for microsatellite loci. A standard panel of
microsatellite markers, including mononucleotide and
dinucleotide repeats, has been recommended and established
guidelines are used to identify MSI phenotype [15]. Three levels
of MSI can be identified: high-level MSI (MSI-H), generally
defined as MSI in more than 30% of the standard markers; low-
level MSI (MSI-L), when changes are exhibited in less than 30%
of the markers and microsatellite stable (MSS) in the absence of
microsatellite alterations [15, 16]. Recently, mononucleotide
repeat markers have been shown to be highly sensitive in
detecting MSI-H tumors [17, 18] and revised criteria have been
proposed in order to define MSI-H as instability at
mononucleotide loci and MSI-L as instability limited at only
dinucleotide loci [19]. By adopting these criteria, we reported
a frequency of 17% MSI-H, 14% MSI-L and 69% MSS in a series
of GC cases from a high-risk population in central Italy [20].
These frequencies are consistent with frequencies observed in
other GC series from Western populations [14].
In colon cancer MSI is caused by mutations in the main DNA
mismatch repair (MMR) genes hMLH1 and hMSH2, and less
frequently in hMSH6, hPMS1 and hPMS2 genes [16]. By
contrast, in GC hMLH1 and hMSH2 mutations are relatively
rare being reported in about 15% and 12% of MSI-H GCs,
respectively [7, 14, 21–23]. However, hMLH1 silencing, due to
promoter hypermethylation, has been found to be responsible
for the development of the majority, more than 50%, of GCs
exhibiting MSI-H phenotype [7, 14, 22, 24–26]. Moreover,
MSI-H GCs show a lack of hMLH1 and/or hMSH2 protein
expression [22, 27], thus suggesting gene expression
inactivation by alternative genetic or epigenetic alterations
[7, 14, 21, 22, 24, 25, 28–32]. Overall, it is noteworthy to point
out the role exerted by MMR protein immunohistochemistry
in identifying MSI-H GCs [14, 32].
Simple genetic and/or epigenetic inactivation of MMR genes
is not, by itself, a transforming event and therefore additional
genetic changes are believed to be necessary for progression to
Figure 1. Patterns of genomic instability (MSI and CIN) in the multistep process of gastric carcinogenesis following an intestinal
metaplasia–adenoma–carcinoma sequence.
Figure 2. Relationships between known genomic instability pathways
(CIN and MSI) in gastric cancer. Percentages of GCs showing overlap
between the CIN and MSI pathways are reported.
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malignancy (Figure 1). MSI-H GCs progress through mutations
in coding repetitive sequences in genes involved in cell growth
regulation (TGFbRII, IGFIIR, RIZ, TCF4, DP2), in apoptosis
(BAX, BCL 10, FAS, CASPASE 5, APAF 1) and in DNA repair
genes (hMSH6, hMSH3, MED1, RAD50, BLM, ATR, MRE11)
[20, 33–36]. These mutations disrupt gene expression and
confer cell growth advantage and clonal perpetuation. In most
cases, mutational events inactivate only one of the two alleles of
these genes thus leading to haploinsufficiency. As
a consequence, these mutations may tip the balance of
regulatory pathway and drive cells to further progress in
malignancy [36]. This assumption has been corroborated by the
experimental verification of functional consequences of MSI-
related mutations in some of the most frequently targeted genes
[35, 36]. MSI-related mutations occurring at the TGFbRII and
BAX genes confer cell growth advantage, by disrupting TGFb
cell growth control and Bax-dependent apoptosis, mutations at
the MMR repair genes, hMSH6 and hMSH3, increase mutations
rate in MSI-H tumor cells [36] and mutations at ATR gene
abrogate ATR-dependent DNA damage response by
a dominant-negative manner [37]. The occurrence of mutations
in specific sets of cancer-related genes confers unique clinico-
pathological features to MSI-H GCs in contrast to MSS and
MSI-L GCs. In fact, intestinal histotype, antral location,
expanding type, lower prevalence of lymph-node metastases,
H. pylori seropositivity have been associated with MSI-H GCs
[27, 38, 39]. Moreover, MSI-H GC cases show a relatively
improved long-term survival compared with MSS/MSI-L
counterparts [27, 39, 40]. This seems to be related to an
increased host immune response [41]. In fact, alterations in
MMR may be responsible for the production, by tumor
cells, of abnormal tumor-specific peptides, which recruit
lymphocytes in the tumor and induce an immune response.
Thus, activation of cytotoxic lymphocytes within the tumor may
lead to increased apoptotic cell death of neoplastic cells [41].
chromosomal instability phenotype in
gastric cancer
Chromosomal instability (CIN) is the most common type of
genomic instability observed in human cancers and CIN
phenotype has been reported in at least 60% of gastrointestinal
tumors [42]. CIN is characterized by changes in chromosome
copy number (aneuploidy) and alterations in chromosomal
regions, including allelic losses (LOHs), gene deletions and/or
amplifications. These alterations may induce oncogenes
activation and/or tumor suppressor gene inactivation. The
identification of specific patterns of chromosome gains/losses
occurring during progression from adenoma to carcinoma and
the observation that CIN is an early event in tumor formation
that increases with tumor progression are consistent with the
idea that CIN is a relevant pathogenic process in GC. Despite the
high frequency and the fact that CIN has been considered
a hallmark of cancer, our knowledge of the molecular basis of
CIN in GC is still incomplete.
Molecular mechanisms underlying CIN may include
mechanisms involved in the regulation of mitotic spindle
checkpoints and, in particular, genes that control kinetochore
structure and function, centrosome and microtubule formation,
chromosome condensation, sister chromatid cohesion and cell
cycle checkpoints. APC is one of the major genes involved in the
regulation of chromosome segregation [43]. Cells carrying APC
mutations may acquire structural alterations in chromosomes
and aneuplody [44]. APC mutations have been observed in
about 10% of GC [45]. p53 is one of the most important genes
involved in the regulation of the mitotic checkpoint [46, 47].
p53 point mutations are observed in 30%–50% GCs and p53
locus is targeted by LOH in 60% of GCs [45, 48]. Inactivation of
proteins involved in DNA damage checkpoints, chromosome
metabolism and centrosome function, cell proliferation,
apoptosis, cell adhesion and in neoangiogenesis has also been
shown to be involved in CIN pathway [49, 50]. The progression
of CIN positive (CIN+) GC is characterized by frequent LOH at
the APC locus (30%–40%) [48] and, at the lower level (3%–
20%), by K-ras activating point mutations, specifically at codons
12, 13, 59 e 61 [51, 52] (Figure 1).
Interestingly, CIN has been demonstrated to be a valuable
prognostic factor and tumor stage indicator in GC. In fact,
survival is reduced in GC cases with a high CIN level [53],
supporting the hypothesis that, in GC tumor progression, and
consequentially survival, correlates with the accumulation of
genomic instability.
At the molecular level, CIN can be analyzed by using screening
methods that allow the detection of alterations in the whole
genome (AP-PCR technique) or at predefined genomic regions
Figure 3. Model showing a link between epigenetic and genetic alterations in gastrointestinal cancer pathogenesis (modified by Suzuki et al. [13]).
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(LOH analysis). Both screening techniques are performed on
paired normal and tumor DNA. By using AP-PCR technique,
a DNA fingerprint is obtained and DNA defects, both losses or
gains, are detected in the whole genome of the tumor cell due to
the arbitrary nature of priming events. AP-PCR generates a sort
of molecular karyotype-defined amplotype [53]. The presence of
CIN phenotype is defined as genomic damage fraction (GDF).
GDF is calculated as the ratio between the number of altered
bands over the total number of bands amplified using arbitrary
primer sets. LOH analysis is based on the screening of a panel of
microsatellite markers selected from a subset of chromosomal
regions that are known to be frequently targeted by LOH.
In GC, common markers are selected in chromosomes 3q, 4p,
5q, 8p, 9p, 13q, 17p and 18q [54, 55]. The presence of CIN
can be defined by calculating the fractional allelic loss (FAL)
represented by the ratio between the number of LOH events
over the total number of informative loci analyzed [42].
By combining AP-PCR and LOH analysis, we recently
evaluated the presence of CIN phenotype in a series of 62 GC
cases from southern Italy, already characterized for MSI
phenotype [56]. Overall, 14% of GC were MSI-H and 50% of
GCs were CIN+ (unpublished data). Interestingly, both MSI-H
and CIN+ phenotype were observed in 4% of GC and a relatively
high proportion of GCs tested (60%) was MSS and CIN-
(unpublished data). These data are consistent with evidence
indicating that, in GC, MSI and CIN phenotypes are not always
independent pathways and that additional mechanisms may
contribute to gastric carcinogenesis [11] (Figure 2).
CpG islands methylator phenotype in
gastric cancer
Hypermethylation of CpG islands is associated with silencing of
many genes and has been proposed as an alternative mechanism
to inactivate tumor-related genes in human cancers. Epigenetic
silencing of tumor-related genes due to CpG islands
hypermethylation is one of the most important epigenetic
alterations in cancer development [57]. Recent studies have
indicated that, in gastric carcinogenesis, DNA hypermethylation
is a crucial mechanism in transcriptional silencing of tumor-
related genes, such as p16 on chromosome 9p21, and the
MMR gene hMLH1 on chromosome 3p21 [58]. Concurrent
hypermethylation in multiple loci has been defined as CpG
island methylation phenotype positive (CIMP-positive) and
have been identified in GC [59–62]. Hypermethylation of gene
promoters progressively increases with histopathologic
progression from chronic gastritis, intestinal metaplasia,
adenoma and carcinoma, suggesting a distinct pathway in
gastric carcinogenesis and progression [58, 63].
Originally, CIMP-positive GC was defined as a tumor with
methylation at more than three loci methylated in tumors
(MINT) [61]. More recently, in order to define CIMP tumors as
a group characterized by distinct genetic, morphological or
clinical characteristics compared to tumors with other
predominant forms of genomic instability [64], the definition of
CIMP-positive as been suggested to be quantitative and a low
CIMP level (CIMP-L) and high CIMP level (CIMP-H) can be
identified if less than 50% and more than 50% of genes/loci were
respectively methylated. A quantitative approach has recently
been used in order to investigate the difference in terms of
clinicopathologic features between GC with high numbers of
DNA methylated genes and CIMP-positive. GCs were analyzed
either according to the number of methylated genes above the
average number of methylated genes per tumor (high-
methylated group) and the original definition of CIMP-positive
cases [63]. No association has been found between tumor
stage and DNA methylation of individual genes or using the
original CIMP definition. In contrast, accumulation of DNA
methylation of tumor-related genes is associated with tumor
stage, suggesting that methylation of tumor related genes
accumulates with tumor progression [63]. Overall, these
findings indicate that GCs with a higher number of methylated
genes have more distinct DNA methylation profile than the
originally defined CIMP-positive GCs. However, little is still
known about the correlation between DNA methylation of
multiple genes and clinicopathologic features of GC.
Intriguingly, it has been reported that concurrent
hypermethylation of gene promoters is associated with MSI-H
phenotype in GC [65] and concordant methylation of multiple
genes/loci (CIMP-H) is associated with better survival but is not
an independent predictor of prognosis in GC [58].
More recently, the relationships between genetic and
epigenetic alterations in colon and gastric cancer were
investigated by using AP-PCR and methylation-sensitive
amplified fragment length polymorphism (MS-AFLP), this
latter technique allowing the analysis of over 150 random CpG
loci. DNA hypomethylation and hypermathylation alterations
were found to distribute gradually and increased with cancer
patient age, in contrast with the age-independent genomic
alterations. Increased DNA hypomethylation and
hypermethylation have been shown to correlate with increased
genomic damage and, in particular, a global DNA
demethylation has been shown to precede genomic damage
[13]. Thus a model for linking epigenetic and genetic alterations
in gastrointestinal carcinogenesis may be proposed. Following
this model, in MSS tumors the gradual and age-dependent
increase in global DNA demethylation may increase the
probability of occurrence of the genomic alterations associated
with tumor development and progression and on the other
hand, in MSI+ tumors, without genetic inactivation of MMR
genes, hypermethylation of CpG islands may cause the MSI
phenotype by hMLH1 silencing (Figure 3).
patterns of genomic instability in
gastric cancer: clinical implications
Understanding the molecular basis underlying gastric
carcinogenesis is fundamental for identify new diagnostic and
prognostic molecular markers as well as novel treatment
modalities for GC patients. The evidence of different patterns of
genomic instability in GC may allow the identification of
specific GC subsets characterized by peculiar molecular
alterations and clinico-pathological features and this
information may indicate improved therapeutic approaches for
patient care. In this respect, MSI is a promising screening tool.
In fact, MSI-H GCs identify a well-defined subset of GC
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characterized by unique clinico-pathological features including
intestinal histotype, antral location, lower prevalence of
lymph-node metastases and, importantly, MSI-H GC cases
show a relatively improved long-term survival compared with
MSS/MSI-L counterparts. Thus, a role for MSI as molecular
tumor and prognostic marker seems to be promising. MSI can
also be used as a marker for the screening of genetic instability,
and identifying patients with genetic instability may help to
identify at-risk patients. Moreover, MSI detection is a very
promising tool for early diagnosis of GC considering that it can
be detected in both gastric adenoma and intestinal metaplasia,
which are precancerous lesions associated with well-
differentiated GC. In this regard, it is noteworthy that the
presence and the extent of MSI, but also CIN phenotype,
evaluated on endoscopic biopsy specimen from GC patients,
was shown to provide valuable information for making
a preoperative genetic diagnosis of GC [55].
GC is a heterogeneous disease and may be amenable to
different therapeutic treatments depending upon tumor
mutational profiles, particularly whether they display MSI, CIN
or CIMP phenotype. Currently, there is no consensus whether
adjuvant therapy is differentially beneficial for patients with
MSI + or MSI- GC. However, in vitro data suggest that MSI+
and CIN+ cancers differ in their response to therapy-induced
DNA damage, and MSI+ cancers are relatively insensitive to
5-fluorouracil [66]. From a clinical standpoint, DNA
methylation changes in GC represent an attractive therapeutic
target, as epigenetic alterations are, in theory, reversible by
using DNA methylation inhibitors, which have been
demonstrated to restore gene expression and exert antitumor
effects in vitro and in vivo laboratory models [67].
In conclusion, a more complete understanding of the basis
of genomic instability and aberrant methylation of cancer
genome has yet to be achieved and the translation of molecular
genetics to new diagnostic, prognostic and therapeutic
modalities remains a challenge.
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